LOGIN  |  REGISTER
Viking Therapeutics
Compass Therapeutics

Streamline Health® Announces New RevID™ Contract With Georgia-Based Healthcare Provider

September 27, 2023 | Last Trade: US$3.59 0.02 -0.55
  • 68-bed Georgia-based healthcare provider selected RevID’s automated charge reconciliation to help eliminate revenue leakage
  • Closed in collaboration with large channel partner

Atlanta, GA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has signed a new contract for the use of RevID, with a 68-bed, healthcare provider serving southern Georgia. The contract was the second to close in collaboration with one of Streamline’s large channel partners since June of 2023.

Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. RevID’s automated charge reconciliation ensures that providers can accurately capture, bill and ultimately be paid for all the care they provide.

“We are pleased to support the revenue cycle of another healthcare provider, and that our large channel partner is generating sales momentum,” stated Ben Stilwill, President, Streamline Health. “We look forward to the continued expansion of our client-base to help our nation’s hospitals put an end to lost revenue.”

About Streamline Health

Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net

To Learn More

Media
David Kosloski
Vice President, Marketing & Communications
651.308.1395
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investors
Jacob Goldberger
Director, Investor Relations and FP&A
303.887.9625
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page